68
Views
0
CrossRef citations to date
0
Altmetric
Corrigendum

Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study [Corrigendum]

Page 869 | Published online: 22 Apr 2020
This article refers to:
Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study

Bloom CI, Douglas I, Usmani OS, Quint JK. Int J Chron Obstruct Pulmon Dis. 2020;15:701–710.

The authors have advised that there should be an added Funding section. The funding statement is as follows:

Funding

This study was funded by an Investigator Initiated Study from Chiesi. Chiesi had no role in the design, analysis, interpretation of findings or writing of the manuscript.

On page 709 the disclosure section should be presented as follows:

Disclosure

OSU and JKQ are co-last authors to this study. JKQ reports funding outside the submitted work from AstraZeneca, Asthma UK, The Health Foundation, MRC, Wellcome Trust, BLF, GlaxoSmithKline, Insmed, Bayer, IQVIA, and Boehringer Ingelheim and funding from AstraZeneca, GlaxoSmithKline, Chiesi, Bayer, Teva, and Boehringer Ingelheim for Advisory board participation or travel. ID reports grants outside the submitted work from NIHR, GlaxoSmithKline, MRC, ABPI. OSU reports from outside the submitted work grants from AstraZeneca, Edmond Pharma and GlaxoSmithKline; personal fees from Aerocrine, Boehringer Ingelheim, Cipla, Mundipharma, Napp, Sandoz, Takeda and Zentiva. The authors report no other conflicts of interest in this work.

The authors apologize for these errors.